TRPA1 in Chemotherapy-Induced Peripheral Neuropathy: A Promising Target for Immunomodulation and Anti-Inflammatory Therapy.

Chemotherapy-induced peripheral neuropathy (CIPN) is a painful condition affecting many cancer patients undergoing chemotherapy treatment. It causes abnormal pain in the hands and feet, along with increased sensitivity to hot and cold temperatures. This study examines a specific protein receptor called TRPA1 that appears to play a key role in developing these symptoms.

Researchers discovered that TRPA1 acts as an injury receptor that becomes activated by oxidative stress, inflammation, and cold temperatures during chemotherapy. When activated, this receptor triggers a cascade of inflammatory responses, releasing factors that lead to nerve inflammation and pain signaling throughout the body. Understanding this mechanism is important because currently there are very few effective clinical treatments available for CIPN.

The study explores the possibility of targeting TRPA1 as a new treatment approach for CIPN. By blocking or inhibiting this receptor, it may be possible to reduce the neuroinflammation that causes pain and sensitivity. The researchers examined both TRPA1 antagonist drugs and natural herbs as potential treatment options.

For patients considering acupuncture, this research is relevant because traditional Chinese medicine approaches, including acupuncture and herbal therapy, may work through similar anti-inflammatory pathways. Acupuncture has been shown in various studies to modulate inflammatory responses and reduce chemotherapy-related side effects. The identification of TRPA1 as a key target provides a scientific framework for understanding how complementary therapies might help manage CIPN symptoms by reducing neuroinflammation and regulating immune responses. Patients interested in acupuncture for CIPN should consult with a licensed acupuncturist experienced in oncology support care.

This review examines TRPA1 (transient receptor potential ankyrin 1) as a therapeutic target for chemotherapy-induced peripheral neuropathy. TRPA1 functions as an injury receptor activated by oxidative stress, inflammatory mediators, and hypothermic conditions during CIPN pathogenesis. Upon activation, TRPA1 modulates downstream inflammatory pathways, promoting release of inflammatory factors and neuropeptides that contribute to abnormal immune regulation, neurogenic inflammation, and pain signaling in distal limbs.

The study explores targeting TRPA1 through antagonists and natural herbs to inhibit neuroinflammation in CIPN management. Given the limited clinical treatment options currently available, this mechanism represents a promising intervention point. For practitioners, understanding TRPA1's role in CIPN provides a molecular framework for treatment strategies. Acupuncture's known anti-inflammatory and immunomodulatory effects may partially operate through similar pathways, making it a relevant adjunctive therapy. Clinical application should focus on reducing neuroinflammation, modulating immune responses, and addressing cold sensitivity. This research supports integrative approaches combining conventional and complementary modalities for CIPN management.